Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume $41.11 +0.07 (+0.17%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Protagonist Therapeutics Short Interest DataProtagonist Therapeutics (PTGX) has a short interest of 3.28 million shares. This marks a 9.33% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.5, indicating that it would take 5.5 days of the average trading volume of 504,820 shares to cover all short positions.Current Short Interest3,280,000 sharesPrevious Short Interest3,000,000 sharesChange Vs. Previous Month+9.33%Dollar Volume Sold Short$150.36 millionShort Interest Ratio5.5 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares59,600,000 sharesPercentage of Shares Shorted5.50%Today's Trading Volume1,086,776 sharesAverage Trading Volume504,820 sharesToday's Volume Vs. Average215% Short Selling Protagonist Therapeutics? Sign up to receive the latest short interest report for Protagonist Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPTGX Short Interest Over TimePTGX Days to Cover Over TimePTGX Percentage of Float Shorted Over Time Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Protagonist Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20243,280,000 shares $150.36 million +9.3%N/A5.5 $45.84 10/15/20243,000,000 shares $142.92 million -14.8%N/A4.6 $47.64 9/30/20243,520,000 shares $158.40 million +9.0%N/A5.2 $45.00 9/15/20243,230,000 shares $151.87 million -1.5%N/A3.4 $47.02 8/31/20243,280,000 shares $140.68 million +5.8%N/A3.5 $42.89 8/15/20243,100,000 shares $125.83 million +6.9%N/A3.2 $40.59 Get the Latest News and Ratings for PTGX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20242,900,000 shares $108.58 million -11.0%N/A3.1 $37.44 7/15/20243,260,000 shares $119.81 million +59.8%N/A3.6 $36.75 6/30/20242,040,000 shares $70.69 million -34.6%N/A2.4 $34.65 6/15/20243,120,000 shares $104.18 million -7.7%N/A5.3 $33.39 5/31/20243,380,000 shares $95.15 million -2.6%N/A5.8 $28.15 5/15/20243,470,000 shares $109.20 million -7.0%N/A6.3 $31.47 4/30/20243,730,000 shares $93.66 million +6.0%N/A6.6 $25.11 4/15/20243,520,000 shares $93.56 million +2.3%N/A5.2 $26.58 3/31/20243,440,000 shares $99.52 million +0.6%N/A4.6 $28.93 3/15/20243,420,000 shares $99.11 million +16.3%N/A4.7 $28.98 2/29/20242,940,000 shares $89.32 million +5.8%N/A3.6 $30.38 2/15/20242,780,000 shares $78.48 million +6.5%N/A3.5 $28.23 1/31/20242,610,000 shares $65.28 million +2.4%N/A3.2 $25.01 1/15/20242,550,000 shares $66.05 million +8.5%N/A3.5 $25.90 12/31/20232,350,000 shares $53.89 million -41.0%N/A3.3 $22.93 12/15/20233,980,000 shares $83.86 million +9.3%N/A5.6 $21.07 11/30/20233,640,000 shares $66.28 million -0.3%N/A5.4 $18.21 11/15/20233,650,000 shares $59.46 million -7.4%N/A5.7 $16.29 10/31/20233,940,000 shares $57.29 million +15.5%N/A6 $14.54 10/15/20233,410,000 shares $52.65 million +8.3%N/A5.3 $15.44 9/30/20233,150,000 shares $52.54 million +12.5%N/A4.5 $16.68 9/15/20232,800,000 shares $50.12 million +1.8%N/A3 $17.90 8/31/20232,750,000 shares $54.51 million -9.2%N/A2.8 $19.82 8/15/20233,030,000 shares $56.84 million +2.0%N/A2.8 $18.76 7/31/20232,970,000 shares $57.62 million -10.5%N/A2.7 $19.40 7/15/20233,320,000 shares $70.55 million +4.4%N/A2.8 $21.25 6/30/20233,180,000 shares $87.83 million +18.2%N/A2.7 $27.62 6/15/20232,690,000 shares $77.15 million -12.1%N/A2.5 $28.68 5/31/20233,060,000 shares $79.77 million -15.0%N/A2.5 $26.07 5/15/20233,600,000 shares $93.49 million -3.2%N/A2.2 $25.97 4/30/20233,720,000 shares $84.07 million -14.7%N/A2.2 $22.60 4/15/20234,360,000 shares $81.71 million +0.5%N/A2.5 $18.74 3/31/20234,340,000 shares $99.82 million -16.1%N/A2.6 $23.00 3/15/20235,170,000 shares $124.34 million +88.7%N/A3.2 $24.05There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t 2/28/20232,740,000 shares $44.44 million +5.4%6.3%1.9 $16.22 2/15/20232,600,000 shares $42.43 million +2.0%6.0%2.5 $16.32 1/31/20232,550,000 shares $33.89 million +25.6%5.9%2.7 $13.29 1/15/20232,030,000 shares $24.71 million +14.0%4.7%2.4 $12.17 12/30/20221,780,000 shares $19.42 million -4.3%4.1%2.3 $10.91 12/15/20221,860,000 shares $17.73 million +6.9%4.3%2.4 $9.53 11/30/20221,740,000 shares $13.76 million -4.4%4.0%2.2 $7.91 11/15/20221,820,000 shares $14.63 million -7.6%4.2%2.4 $8.04 10/31/20221,970,000 shares $15.96 million -11.7%4.5%2.5 $8.10 10/15/20222,230,000 shares $17.82 million -8.2%5.1%2.6 $7.99 9/30/20222,430,000 shares $20.48 million -13.5%5.6%2.7 $8.43 9/15/20222,810,000 shares $23.24 million +9.3%6.5%2.8 $8.27 8/31/20222,570,000 shares $22.41 million -11.4%5.9%2.4 $8.72 8/15/20222,900,000 shares $32.86 million -31.6%6.7%2.7 $11.33 7/31/20224,240,000 shares $42.19 million -13.1%N/A3.5 $9.95 7/15/20224,880,000 shares $46.16 million +2.3%N/A3.5 $9.46 6/30/20224,770,000 shares $37.73 million +18.4%N/A3.4 $7.91 6/15/20224,030,000 shares $30.14 million +18.9%N/A3 $7.48 5/31/20223,390,000 shares $29.70 million +1.5%N/A2.9 $8.76 5/15/20223,340,000 shares $29.43 million +1.5%N/A2.9 $8.81 4/30/20223,290,000 shares $29.91 million +20.5%N/A3.1 $9.09 4/15/20222,730,000 shares $54.46 million -16.3%N/A3.3 $19.95 3/31/20223,260,000 shares $77.20 million -17.5%N/A4.6 $23.68 3/15/20223,950,000 shares $101.99 million -0.8%N/A5.7 $25.82 2/28/20223,980,000 shares $96.63 million -19.1%N/A5.6 $24.28 2/15/20224,920,000 shares $141.35 million +25.5%N/A7.3 $28.73 1/31/20223,920,000 shares $114.82 million +9.5%N/A6.4 $29.29 1/15/20223,580,000 shares $128.74 million +10.2%N/A5.9 $35.96 12/31/20213,250,000 shares $111.15 million +2.2%N/A2.4 $34.20 12/15/20213,180,000 shares $97.12 million +2.6%N/A2.2 $30.54 11/30/20213,100,000 shares $104.22 million -17.6%7.3%1.6 $33.62 11/15/20213,760,000 shares $134.38 million -15.1%8.8%1.9 $35.74 10/29/20214,430,000 shares $138.04 million +18.5%10.5%2.3 $31.16 10/15/20213,740,000 shares $115.83 million +2.8%8.9%2 $30.97 9/30/20213,640,000 shares $64.50 million +27.3%8.7%2.1 $17.72 9/15/20212,860,000 shares $132.90 million -6.5%6.8%3 $46.47 8/31/20213,060,000 shares $148.41 million -4.4%7.3%7.3 $48.50 8/13/20213,200,000 shares $152.61 million +5.6%7.6%7.3 $47.69 7/30/20213,030,000 shares $149.77 million -11.1%7.3%6.9 $49.43 7/15/20213,410,000 shares $150.93 million -1.7%8.3%8.1 $44.26 6/30/20213,470,000 shares $155.73 million -1.4%8.5%8.5 $44.88 6/15/20213,520,000 shares $134.29 million -3.8%8.6%9.3 $38.15 5/28/20213,660,000 shares $128.50 million -6.2%9.7%11.6 $35.11 5/14/20213,900,000 shares $113.10 million +26.2%N/A12.2 $29.00 4/30/20213,090,000 shares $92.67 million +1.6%N/A9.2 $29.99 4/15/20213,040,000 shares $79.01 million +0.3%N/A9.1 $25.99 3/31/20213,030,000 shares $76.69 million +5.6%N/A8.5 $25.31 3/15/20212,870,000 shares $88.97 million +3.6%N/A6.4 $31.00 2/26/20212,770,000 shares $66.45 million -0.4%N/A5.6 $23.99 2/12/20212,780,000 shares $69.75 million +1.5%N/A5.9 $25.09There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t 1/29/20212,740,000 shares $58.25 million -13.6%N/A5.7 $21.26 1/15/20213,170,000 shares $72.43 million -7.9%N/A6.6 $22.85 12/31/20203,440,000 shares $68.77 million +28.4%N/A7.6 $19.99 12/15/20202,680,000 shares $56.07 million +6.8%N/A6.6 $20.92 11/30/20202,510,000 shares $59.86 million -1.6%N/A6.9 $23.85 11/15/20202,550,000 shares $56.64 million No ChangeN/A7.2 $22.21 10/30/20202,550,000 shares $47.15 million -6.9%N/A7.2 $18.49 10/15/20202,740,000 shares $57.46 million -16.5%N/A7.9 $20.97 9/30/20203,280,000 shares $64.12 million +45.8%N/A9.5 $19.55 9/15/20202,250,000 shares $48.74 million +16.0%N/A6.3 $21.66 8/31/20201,940,000 shares $43.46 million +12.1%N/A5.4 $22.40 8/14/20201,730,000 shares $27.14 million +8.8%N/A4.2 $15.69 7/31/20201,590,000 shares $25.01 million +15.2%N/A2.8 $15.73 7/15/20201,380,000 shares $21.51 million +4.6%N/A1.3 $15.59 6/30/20201,320,000 shares $23.31 million -9.6%N/A1.2 $17.66 6/15/20201,460,000 shares $23.51 million +29.2%N/A1.4 $16.10 5/29/20201,130,000 shares $18.69 million -11.7%N/A1.2 $16.54 5/15/20201,280,000 shares $20.74 million +14.3%N/A1.4 $16.20 4/30/20201,120,000 shares $7.56 million -13.9%5.4%1.5 $6.75 4/15/20201,300,000 shares $8.87 million +4.0%6.3%8.6 $6.82 3/31/20201,250,000 shares $8.14 million -8.2%6.1%7.5 $6.51 3/13/20201,362,300 shares $9.47 million +14.5%7.0%9.5 $6.95 2/28/20201,190,000 shares $7.14 million -11.9%6.1%5.7 $6.00 2/14/20201,350,000 shares $10.30 million +3.9%6.9%2.1 $7.63 1/31/20201,300,000 shares $10.82 million +4.8%6.9%2 $8.32 1/15/20201,240,000 shares $10.39 million -20.5%6.5%1.9 $8.38 12/31/20191,560,000 shares $11.73 million +39.3%8.2%2.4 $7.52 PTGX Short Interest - Frequently Asked Questions What is Protagonist Therapeutics' current short interest? Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 3,280,000 shares of PTGX short. Learn More on Protagonist Therapeutics' current short interest. What is a good short interest ratio for Protagonist Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 6.0. Learn More on Protagonist Therapeutics's short interest ratio. Which institutional investors are shorting Protagonist Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Protagonist Therapeutics: Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Protagonist Therapeutics' short interest increasing or decreasing? Protagonist Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 3,280,000 shares, an increase of 9.3% from the previous total of 3,000,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Protagonist Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Protagonist Therapeutics: Amphastar Pharmaceuticals, Inc. (12.16%), Calliditas Therapeutics AB (publ) (0.01%), Phibro Animal Health Co. (2.03%), Esperion Therapeutics, Inc. (17.16%), Cara Therapeutics, Inc. (2.06%), Revolution Medicines, Inc. (10.78%), Qiagen (1.61%), Intra-Cellular Therapies, Inc. (2.23%), Roivant Sciences Ltd. (12.38%), Ascendis Pharma A/S (5.62%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Protagonist Therapeutics stock? Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Protagonist Therapeutics? A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further. How often is Protagonist Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Amphastar Pharmaceuticals Short Interest Calliditas Therapeutics AB (publ) Short Interest Phibro Animal Health Short Interest Esperion Therapeutics Short Interest Cara Therapeutics Short Interest Revolution Medicines Short Interest Qiagen Short Interest Intra-Cellular Therapies Short Interest Roivant Sciences Short Interest Ascendis Pharma A/S Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTGX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
